Telfast® 24 Hour 180mg Tablets
Get all-day relief from allergy symptoms with Telfast® 24 Hour 180 mg Tablets.¹
Relieve your hay fever and allergy symptoms like runny nose, sneezing, itchy, watery eyes, itchy nose, or itchy throat.² That is why allergist recommend oral second-generation/less sedating antihistaminesfor patients with AR and primary complaints of sneezing and itching.³ ‡
Non-sedating.²
24-hour relief.¹§
Relieves indoor and outdoor seasonal allergic rhinitis symptoms.²
§Starts working in one hour.²
‡ Among Over-the-Counter oral antihistamines medications.
WHERE TO BUY
Product Information
- Dose adjustment is not required in the elderly or in patients with hepatic or renal impairment.²
- Do not take more than directed
- Safety sealed: do not use if carton is opened or if printed foil inner seal on bottle is torn or missing.
- Store at temperature not exceeding 30 C.2
- Protect from excessive moisture.
- Use as directed
Do not use if you have ever had an allergic reaction to this product or any of its ingredients.
When using this product:
Stop use and ask a doctor if an allergic reaction to this product occurs. Seek medical help right away.²
If pregnant or breastfeeding
Use in Lactation: Telfast is not recommended for nursing women unless, in the physician's judgment, the potential benefit to the patient outweighs the potential risk to the infant. There are no data on the content of human milk after administering fexofenadine. However, when terfenadine was administered to nursing mothers, fexofenadine was found to cross into human breast milk.
Exposure of rats to fexofenadine and terfenadine through the administration of terfenadine at dietary doses of 150 and 300 mg/kg/day throughout pregnancy and lactation (corresponding to systemic exposure at levels (AUC) approximately 3- and 6-fold higher than those anticipated in clinical use) caused decreased pup weight gain and survival. The relative risks of these effects from terfenadine or fexofenadine are unknown. Effects on pups exposed to fexofenadine only during lactation are unknown.
Use in Pregnancy: Category B2. Reproductive toxicity of fexofenadine in animals was assessed through terfenadine exposure. No evidence of teratogenicity was observed in animal reproduction studies (rat and rabbit) when terfenadine was given at oral doses of up to 300 mg/kg/day throughout organogenesis, which corresponds to levels of systemic fexofenadine exposure 4- and 32-fold higher, respectively, than those anticipated in clinical use. Decreased pup weight and survival occurred in rats when terfenadine was given at oral doses of 150 mg/kg/day and above throughout pregnancy and lactation.There are no studies in pregnant women exposed to fexofenadine alone or through the administration of terfenadine.
Keep out of reach of children. In case of overdose, Standard measures to remove any unabsorbed drug should be employed. Symptomatic and supportive treatment is recommended.²
Ingredients
*avoid allergic triggers like pets’ dander
Active Ingredients
Fexofenadine HCl 180 mg (in each tablet)
An antihistamine that works to relieve allergy symptoms of sneezing, runny nose, itchy/watery eyes, and itchy nose or throat due to hay fever or other upper respiratory allergies.2
Purpose: Antihistamine
Inactive ingredients
Croscarmellose sodium, hypromellose, Pink iron oxide blends, magnesium stearate, microcrystalline cellulose, colloidal anhydrous silica, povidone, pregelatinized maize starch, titanium dioxide and yellow iron oxide blend .2
Frequently Asked
Questions
-
No. Use Telfast® only as directed.
-
Do not cut or break Telfast®products in half. Use only as directed.
-
No. Telfast® is approved for human use only. Please refer to the product label and use as directed.
Get tips for managing indoor and outdoor allergies
Also available in a 24-hour 180mg formula
1. Cauwenberge V, STAR STUDY INVESTIGATING GROUP. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clinical & Experimental Allergy. 2000 Jun;30(6):891-9.
2. Telfast Ministry of Health Approved Leaflet, approval date: 29/11/2018
3. Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, Dawson DE, Dykewicz MS, Hackell JM, Han JK, Ishman SL. Clinical practice guideline: allergic rhinitis. Otolaryngology–Head and Neck Surgery. 2015 Feb;152(1_suppl):S1-43.
Approved by Egyptian Drug Authority: HF0253OA300/102022. Invalidation date: 20/10/2023. Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg
HF0253OA300/102022
20/10/2023